GSK: Continue to deepen the field of central nervous system to bring better choices for patients

From November 5th to 10th, 2021, the 4th China International Import Expo (hereinafter referred to as the "CIIE") will be held in Shanghai
.
At this CIIE, GSK showcased all aspects of its innovative research and development achievements in the field of central nervous system and supported China's efforts in disease prevention and treatment
.
During the period, the GSK booth also held the "Central Nervous System-related Knowledge Popularization Activity".
Professor Chen Jun, chief physician of Shanghai Mental Health Center, and Professor Xu Jiwen, chief physician of functional neurosurgery of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, were invited to visit the site to discuss the central nervous system.
In-depth discussions and exchanges on diseases related to the nervous system, hoping to use the extensive influence of the CIIE to enhance public awareness of diseases such as epilepsy and bipolar disorder, and help achieve the goal of "Healthy China 2030"
.
01 Focusing on patients and continuing to fill unmet needs.
In 1995, GSK launched paroxetine hydrochloride tablets (trade name: Celote) for depression in China; in 1996, lamotrigine tablets (commodity) for the treatment of epilepsy Name: Rapidone) was also approved for listing; in 2015, GSK successfully marketed Ropinirole hydrochloride sustained-release tablets (trade name: Libei) for the treatment of Parkinson's disease.
.
.
In the field of central nervous system, In addition to launching a variety of classic drugs, GSK has also been constantly striving for innovation
.
In 2012, GSK launched the dosage form of Celodex enteric-coated sustained-release tablets in China.
This dosage form benefits more patients with depression and improves the compliance of patients with medication.
In 2018, GSK Rapidone Dispersible Tablets were approved in China.
Dispersible tablets have the advantages of ordinary tablets and liquid preparations.
They quickly disintegrate into small particles and form a uniform suspension when exposed to water.
The taste of blackcurrant makes it easier for children and patients to accept it.
It is also easy to take for the elderly who have difficulty swallowing.
Their treatment acceptance and compliance
.
In March 2021, GSK's new indication for Rapidone was approved in China, which is suitable for controlling the recurrence or resurgence of emotional episodes in adults with bipolar disorder
.
At present, there are nearly 9 million patients with epilepsy and nearly 8.
5 million patients with bipolar disorder in China, which is a very large burden and challenge for China
.
According to Professor Chen Jun, the chief physician of the Shanghai Mental Health Center, drugs are the main treatment for bipolar disorder at this stage, and bipolar disorder can be effectively controlled on the basis of maintaining medication and psychotherapy
.
Professor Xu Jiwen, chief physician of functional neurosurgery at Shanghai Ruijin Hospital, pointed out that the current epilepsy treatment in China still needs to raise public awareness.
Most patients cannot receive reasonable and effective treatment, and there is a big gap in treatment.
Only 25% of patients are receiving reasonable treatment.
In addition to standard-dose anti-epileptic drug treatment, 41% of patients have never received anti-epileptic drug treatment
.
It is worth noting that whether it is used as a broad-spectrum antiepileptic drug or a drug for the treatment of bipolar disorder, Ribitone has good efficacy and safety.
Authoritative guidelines at home and abroad recommend Ribitone as the first-line drug for long-term treatment of patients
.
Pauline Ng, Medical Director of Prescription Medicines of GSK China, said, “We are very pleased to see that this drug has been approved for bipolar disorder in China this year, helping to solve the current dilemma of limited treatment options for Chinese doctors
.
” Pauline Ng pointed out, “GSK long-term In the field of central nervous system, we see that Chinese patients are facing unmet medical needs
.
In response to these challenges, GSK strives to provide new "keys" to help patients regain peace from the disease and return to normal life
.
" GSK China Core Prescription Drugs Ms.
Huang Jingxuan, the head of the business department, also said, “In order to meet the unmet needs of patients, GSK has been continuously developing new and innovative products, and invested a lot of time, money and energy in this process
.
At the same time, we are committed to In order to solve some of the pain points that patients have not been satisfied in treatment, such as innovation in dosage forms or innovation in indications
.
" 02 Continuous innovation brings better choices to patients.
Since GSK introduced Celeste into the Chinese market in 1995, GSK has worked hand in hand with doctors in the field of central nervous system in China for 26 years, benefiting thousands of Chinese patients
.
At present, the therapeutic drugs in the field of GSK central nervous system cover epilepsy, depression, anxiety, bipolar disorder and Parkinson's
.
At the same time, GSK is also constantly committed to the upgrade of treatment options, including the upgrade of dosage forms and the expansion of indications
.
In addition to launching the first-line treatment plan for epilepsy and bipolar disorder, Rapidone, according to Pauline Ng, GSK will continue to focus on innovation in the treatment of central nervous system (CNS) diseases in the future
.
For example, GSK recently reached a cooperation with a foreign company Alector Corporation to jointly develop monoclonal antibodies—AL001 and AL101—that enhance the precursor of granule protein
.
Among them, AL001 is a potential "first-in-class" monoclonal antibody therapy
.
It targets the receptor protein called sortilin to increase the level of pre-granulin (PGRN) to achieve the treatment of neurodegenerative diseases
.
AL001 is mainly used for the treatment of frontotemporal dementia (FTD), which is a rapidly progressing dementia.
The patient usually develops before the age of 65.
There is currently no feasible treatment plan on the market; AL101 is mainly for different types of frontal dementia.
Patients with temporal lobe dementia, and have been granted orphan drug designation by the FDA for the treatment of FTD in July 2019.
The drug has the potential to be developed for the treatment of Alzheimer’s disease and Parkinson’s disease
.
In addition, GSK has always adhered to the value of "patient-centered", not only bringing innovative drugs to China, but also actively participating in public welfare undertakings, helping China to improve its awareness and standardization of diagnosis and treatment in the fields of epilepsy, bipolar disorder and other diseases.
Actively contribute
.
On the one hand, GSK has a rich product line in the field of central nervous system diseases and continues to innovate to bring better choices to patients
.
On the other hand, GSK is committed to improving China's medical standards by working hand in hand with all parties
.
Ms.
Huang Jingxuan said, “GSK has been continuously working with the Chinese Anti-Epilepsy Association to carry out projects to contribute to the establishment of epilepsy centers at all levels and the improvement of China’s hierarchical diagnosis and treatment system
.
In addition to epilepsy, GSK will also invest more in the field of bipolar disorder, including Implement doctor education to improve the level of disease diagnosis and treatment
.
We believe that every life has the possibility of'doing more and feeling more comfortable'.
What GSK does is to bridge the gap between the needs of patients and the current medical situation, and help them move toward a warm life
.
"